HAEGT

CAS No. 852155-81-8

HAEGT( —— )

Catalog No. M30080 CAS No. 852155-81-8

HAEGT is the first N-terminal 1-5 residues of GLP-1 peptide.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 425 Get Quote
10MG 608 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    HAEGT
  • Note
    Research use only, not for human use.
  • Brief Description
    HAEGT is the first N-terminal 1-5 residues of GLP-1 peptide.
  • Description
    HAEGT is the first N-terminal 1-5 residues of GLP-1 peptide.
  • In Vitro
    HAEGT (0-500 μM) is a competitive substrate for probing prime substrate binding sites of human dipeptidyl peptidase-IV (DPP-IV).HAEGT can be catalyzed cleavage by DPP-IV with a km value of 38 μM, Kcat value of 3.1 S-1.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Glucagon Receptor
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    852155-81-8
  • Formula Weight
    513.5
  • Molecular Formula
    C20H31N7O9
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    Sequence:His-Ala-Glu-Gly-Thr

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • (S, R)-LSN 3318839

    (S, R)-LSN 3318839 is an allosteric modulator of the glucagon-like peptide-3318839 receptor (GLP-1R) that has demonstrated powerful hypoglycemic effects in animal models alone or in combination with sitagliptin.

  • PF-06882961

    PF-06882961 is an orally bioavailable glucagon-like peptide-1 receptor (GLP-1R) agonist. PF-06882961 shows mild to moderate damage to the heart, moderate to severe effects on the thymus gland (which helps with managing infection), mild to moderate stomach ulcers at the highest dose level given in the rat.

  • Tirzepatide

    Tirzepatide (TZP), a novel dual GIP and GLP-1 receptor agonist (RA).